Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wanju Dai

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Pharmacoepidemiology and Drug Safety|October 16, 2003
Benefit-risk analysis: a proposal using quantitative methodsWilliam L Holden, Juhaeri Juhaeri, Wanju Dai
Pharmacoepidemiology and Drug Safety|September 19, 2006
A call for international harmonization in therapeutic risk managementCeri Hirst, Suzanne Cook, Wanju Dai, et al.
Journal of Atrial Fibrillation|May 13, 2017
Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other AntiarrhythmicsShujun Gao, Wanju Dai, Ling Zhang, et al.
The Journal of Rheumatology|October 7, 2004
Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARDGrant W Cannon, William L Holden, Juhaeri Juhaeri, et al.
Clinical Therapeutics|March 4, 2018
Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other AntiarrhythmicsChuntao Wu, Stephanie Tcherny-Lessenot, Wanju Dai, et al.
Clinical Therapeutics|February 4, 2014
Assessment of dronedarone utilization using US claims databasesJasmanda Wu, Jane Thammakhoune, Wanju Dai, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Pharmacoepidemiology and Drug Safety|October 16, 2003
Benefit-risk analysis: a proposal using quantitative methodsWilliam L Holden, Juhaeri Juhaeri, Wanju Dai
Pharmacoepidemiology and Drug Safety|September 19, 2006
A call for international harmonization in therapeutic risk managementCeri Hirst, Suzanne Cook, Wanju Dai, et al.
Journal of Atrial Fibrillation|May 13, 2017
Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other AntiarrhythmicsShujun Gao, Wanju Dai, Ling Zhang, et al.
The Journal of Rheumatology|October 7, 2004
Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARDGrant W Cannon, William L Holden, Juhaeri Juhaeri, et al.
Clinical Therapeutics|March 4, 2018
Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedarone Compared With That in Other AntiarrhythmicsChuntao Wu, Stephanie Tcherny-Lessenot, Wanju Dai, et al.
Clinical Therapeutics|February 4, 2014
Assessment of dronedarone utilization using US claims databasesJasmanda Wu, Jane Thammakhoune, Wanju Dai, et al.
Pageof 1